Form 4 for NSRX Nasus Pharma Ltd
Accepted 2026-04-01 07:31:31 ET · period of report 2026-03-31 · accession 0001493152-26-014503 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 07:31 | 2026-03-31 | NSRX | Teleman Dan Benjamin | CEO, Dir | P - Purchase | $2.04 | +15.0K | 21.2K | +240% | +$30.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-03-31 | P | A | 15,000 | $2.04 | 21,246 | D | — | — |